Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29674744 | 1.00 | GPR119 (0.60) | GPR119CHEK2CYP4F2CYP4A11HDAC1 | |
| SCHEMBL384986 | 0.86 | GPR119 (0.60) | GPR119CHEK2CYP4F2CYP4A11HDAC1 | |
| SCHEMBL29757897 | 0.86 | GPR119 (0.60) | GPR119CHEK2CYP4F2CYP4A11HDAC1 | |
| SCHEMBL20758445 | 0.86 | GPR119 (0.60) | GPR119CHEK2CYP4F2CYP4A11SLC2A1 | |
| SCHEMBL2456170 | 0.86 | GPR119 (0.57) | GPR119CHEK2HDAC1SLC2A1 | |
| SCHEMBL19277455 | 0.84 | CYP4F2 (0.62) | GPR119CHEK2CYP4F2CYP4A11CHRNB2 | |
| SCHEMBL30785455 | 0.84 | GPR119 (0.58) | GPR119CHEK2CYP4F2CYP4A11SLC2A1 | |
| SCHEMBL27158533 | 0.84 | GPR119 (0.58) | GPR119CHEK2CYP4F2CYP4A11SLC2A1 | |
| SCHEMBL384756 | 0.84 | GPR119 (0.66) | GPR119CYP4F2CYP4A11 | |
| SCHEMBL17906592 | 0.84 | GPR119 (0.56) | GPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013743-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114502536-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021030623-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2020-07-28 | — | — | US | disclosed |
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2020-07-28 | — | — | US | disclosed |
| EP-3138834-B1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| EP-3138834-B1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| EP-3074384-B1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-05-22 | — | — | EP | disclosed |
| US-20180318274-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2018-11-08 | — | — | US | disclosed |
| EP-3352750-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2018-08-01 | — | — | EP | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2094683-B1 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC, a Delaware Limited Company (BM) | 2011-09-15 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009038974-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885CHEK2 2703/4885CYP4F2 329/4885 |
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885CHEK2 3476/4885CYP4F2 1881/4885 |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885CHEK2 3476/4885CYP4F2 1881/4885 |
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | GPR119, GLP1R, GCGR | GPR119 1/4885CHEK2 1745/4885CYP4F2 3448/4885 |
| US-20180318274-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | GPR119, GLP1R, GCGR | GPR119 1/4885CHEK2 1745/4885CYP4F2 3448/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885CHEK2 2703/4885CYP4F2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.